Treadwell Therapeutics: Funding, Investors & Team (Oct 2026)
Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer. Founded by a cadre of pre-eminent scientific luminaries, including Dr. Tak W. Mak, the Company's robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945, and a best-in-class TTK inhibitor, CFI-402257, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1. Treadwell also has a robust pre-clinical pipeline with multiple biologic and next-generation TCR-based autologous cell therapy programs.
Treadwell Therapeutics has raised $91.0M across 1 funding round on record, the most recent a Series B of $91.0M announced in Nov 2021.
That round is above the $8.6M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Treadwell Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2021.
Treadwell Therapeutics Funding Rounds
Treadwell Therapeutics Founders and Leadership Team
Contact details for the Treadwell Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Treadwell Therapeutics Funding Compared to Other Biotechnology Startups
Treadwell Therapeutics' latest round of $91.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Treadwell Therapeutics in Biotechnology and New York
Companies Similar to Treadwell Therapeutics
Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…
MEND is a company focused on life sciences, determined to assist individuals in achieving better health…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Treadwell Therapeutics Funding FAQs
What does Treadwell Therapeutics do?
Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer. Founded by a cadre of pre-eminent scientific luminaries, including Dr. Tak W. Mak, the Company's robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945, and a best-in-class TTK inhibitor, CFI-402257, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1. Treadwell also has a robust pre-clinical pipeline with multiple biologic and next-generation TCR-based autologous cell therapy programs.
How much funding has Treadwell Therapeutics raised?
Treadwell Therapeutics has raised $91.0M across 1 round on record. The most recent is a Series B of $91.0M announced in Nov 2021.
When did Treadwell Therapeutics last raise funding?
Treadwell Therapeutics' most recent funding round on record is a Series B of $91.0M, announced in Nov 2021.
Who is the CEO of Treadwell Therapeutics?
Michael Tusche is listed as CEO at Treadwell Therapeutics.
Where is Treadwell Therapeutics headquartered?
Treadwell Therapeutics is based in New York, United States.
How many employees does Treadwell Therapeutics have?
Treadwell Therapeutics is in the 11-50 employee band.
How does Treadwell Therapeutics' funding compare to other Biotechnology startups?
Treadwell Therapeutics' latest round of $91.0M is above the $8.6M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Treadwell Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Treadwell Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.